BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/6/2016 4:13:00 PM | Browse: 1572 | Download: 2720
Publication Name World Journal of Gastroenterology
Manuscript ID 19487
Country Türkiye
Received
2015-05-10 15:11
Peer-Review Started
2015-05-12 16:08
First Decision by Editorial Office Director
Return for Revision
2015-09-14 20:26
Revised
2015-10-05 22:13
Publication Fee Transferred
Editorial Processing by Scientific Editor
2015-10-23 16:43
Final Academic Decision by Editor-in-Chief
2015-10-25 15:43
Publication Technical Verification by Editorial Office Director
2015-11-09 16:59
Articles in Press
2015-11-09 17:00
Edit the Manuscript by Language Editor
2015-11-30 17:58
Typeset the Manuscript
2015-12-16 15:54
Publish the Manuscript Online
2016-01-06 16:13
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Frontier
Article Title Targeted therapies in gastric cancer and future perspectives
Manuscript Source Invited Manuscript
All Author List Ozan Yazici, M Ali Nahit Sendur, Nuriye Ozdemir and Sercan Aksoy
Funding Agency and Grant Number
Corresponding Author Sercan Aksoy, MD, Department of Medical Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara 06100, Turkey. saksoy07@yahoo.com
Key Words Targeted therapies; Antibodies; Gastric cancer; Tyrosine kinase; Survival
Core Tip Trastuzumab was the first molecule shown to prolong both progression-free survival and overall survival in patients with advanced gastric cancer (AGC) when added to first-line chemotherapy in patients with AGC. In 2014, ramucirumab was approved as a single agent or in combination with paclitaxel for the treatment of patients with AGC. Many phase Ⅱ-Ⅲ clinical trials failed to showed activity of different targeted agents in patients with AGC. On the other hand, some molecules have shown promising activity in phase Ⅱ trials and are expected to be in use in the coming years. Pertuzumab and c-Met pathway inhibitors have shown modest activity in a phase Ⅱ trial. The results of two important ongoing phase Ⅲ trials (JACOB and RILOMET-1) may change the recommendations for first-line treatment options in patients with AGC.
Publish Date 2016-01-06 16:13
Citation Yazici O, Sendur MAN, Ozdemir N, Aksoy S. Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016; 22(2): 471-489
URL http://www.wjgnet.com/1007-9327/full/v22/i2/471.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i2.471
Full Article (PDF) WJG-22-471.pdf
Full Article (Word) WJG-22-471.doc